G-protein-coupled Receptor Stimulation of the p42/p44 Mitogen-activated Protein Kinase Pathway Is Attenuated by Lipid Phosphate Phosphatases 1, 1a, and 2 in Human Embryonic Kidney 293 Cells

• Published in: The Journal of biological chemistry 2001-04, Vol.276 (16), p.13452-13460
• Main Authors: Alderton, F, Darroch, P, Sambi, B, McKie, A, Ahmed, I S, Pyne, N, Pyne, S
• Format: Article
• Language: English
• Subjects: Cell Line; Cell Membrane - enzymology; GTP-Binding Proteins - metabolism; Humans; Isoenzymes - metabolism; Kidney; Kinetics; Lysophospholipids - pharmacology; MAP Kinase Signaling System - physiology; Mitogen-Activated Protein Kinase 1 - metabolism; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases - metabolism; Phorbol 12,13-Dibutyrate - pharmacology; Phosphatidate Phosphatase - metabolism; Phosphatidic Acids - pharmacology; Phospholipase D - metabolism; Receptors, Cell Surface - drug effects; Receptors, Cell Surface - physiology; Recombinant Proteins - metabolism; Sphingosine - analogs & derivatives; Sphingosine - pharmacology; Substrate Specificity; Tetradecanoylphorbol Acetate - pharmacology; Transfection; Virulence Factors, Bordetella - pharmacology
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.M006582200

Sphingosine 1-phosphate, lysophosphatidic acid, and phosphatidic acid bind to G-protein-coupled receptors to stimulate intracellular signaling in mammalian cells. Lipid phosphate phosphatases (1, 1a, 2, and 3) are a group of enzymes that catalyze de-phosphorylation of these lipid agonists. It has been proposed that the lipid phosphate phosphatases exhibit ecto activity that may function to limit bioavailability of these lipid agonists at their receptors. In this study, we show that the stimulation of the p42/p44 mitogen-activated protein kinase pathway by sphingosine 1-phosphate, lysophosphatidic acid, and phosphatidic acid, all of which bind to G i/o -coupled receptors, is substantially reduced in human embyronic kidney 293 cells transfected with lipid phosphate phosphatases 1, 1a, and 2 but not 3. This was correlated with reduced basal intracellular phosphatidic acid and not ecto lipid phosphate phosphatase activity. These findings were supported by results showing that lipid phosphate phosphatases 1, 1a, and 2 also abrogate the stimulation of p42/p44 mitogen-activated protein kinase by thrombin, a peptide G i/o -coupled receptor agonist whose bioavailability at its receptor is not subject to regulation by the phosphatases. Furthermore, the lipid phosphate phosphatases have no effect on the stimulation of p42/p44 mitogen-activated protein kinase by other agents that do not use G-proteins to signal, such as serum factors and phorbol ester. Therefore, these findings show that the lipid phosphate phosphatases 1, 1a, and 2 may function to perturb G-protein-coupled receptor signaling per se rather than limiting bioavailability of lipid agonists at their respective receptors.